Audited annual filings, TTM ratios and consensus forward estimates
Wall Street price targets and rating actions
Revenue disaggregation per 10-K filing
Annual filings (FY) with consensus forward estimates (hatched)
1255 daily bars · split adjusted
Current price $0.6497
Latest analyst grade actions
| Date | Firm | Action | Previous | New grade |
|---|---|---|---|---|
| Sep 30, 26 |
Daily · Wilder smoothing
| HC Wainwright & Co. |
| maintain |
| Neutral |
| Neutral |
| Sep 29, 26 | BTIG | maintain | Buy | Buy |
| Mar 18, 26 | HC Wainwright & Co. | downgrade | Buy | Neutral |
| Nov 10, 25 | BTIG | maintain | Buy | Buy |
| May 19, 25 | HC Wainwright & Co. | maintain | Buy | Buy |
| Apr 7, 25 | BTIG | maintain | Buy | Buy |
| Apr 4, 25 | HC Wainwright & Co. | maintain | Buy | Buy |
| Mar 3, 25 | HC Wainwright & Co. | maintain | Buy | Buy |
| Aug 9, 24 | HC Wainwright & Co. | maintain | Buy | Buy |
Classic floor pivots from 2026-10-23
Computed from daily OHLCV bars
| Indicator | Value | Type | Action |
|---|---|---|---|
| RSI (14) | 25.76 | Oscillator | Buy |
| Stochastic %K (14, 3, 3) | 6.04 | Oscillator | Buy |
| Williams %R (14) | -88.05 | Oscillator | Buy |
| MACD (12, 26, 9) | -0.18 (Hist -0.01) | Oscillator | Strong Sell |
| Average Directional Index (14) | 44.07 (+DI 8.4 / -DI 33.2) | Trend | Strong Sell |
| EMA 20 | 0.89 | MA | Strong Sell |
| SMA 20 | 0.91 | MA | Strong Sell |
| EMA 50 | 1.16 | MA | Strong Sell |
| SMA 50 | 1.24 | MA | Strong Sell |
| SMA 200 | 2.37 | MA | Strong Sell |
Stock news · updated daily
Aldeyra Therapeutics, Inc. (NASDAQ:ALDX) shares are trading higher on Tuesday as investors react to the company's intent to submit a formal dispute resolution request tied to its reproxalap program.
Aldeyra Therapeutics, Inc. (ALDX) Discusses FDRR and FDA Review Process for Reproxalap in Dry Eye Disease Transcript
Aldeyra Therapeutics NASDAQ: ALDX said it plans to submit a formal dispute resolution request, or FDRR, to the FDA's Office of New Drugs seeking review of the agency's latest complete response letter for reproxalap, its investigational treatment for the signs and symptoms of dry eye disease.
CONCORD, Mass.--(BUSINESS WIRE)--Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra), a biotechnology company devoted to discovering and developing innovative therapies designed to treat immune-mediated diseases, today announced intent to submit to the U.S. Food and Drug Administration (FDA) a Formal Dispute Resolution Request (FDRR) for reproxalap, an investigational drug candidate, for the treatment of dry eye disease. The FDRR, which is expected to be reviewed by the FDA's Office of New Drug.
CONCORD, Mass.--(BUSINESS WIRE)--Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra), a biotechnology company devoted to discovering and developing innovative therapies designed to treat immune-mediated diseases, today announced that the company will host a regulatory update webcast on Tuesday, September 29, 2026, at 8:00 a.m. ET. The update will focus on reproxalap, an investigational drug for the treatment of dry eye disease. A live audio webcast and slide presentation will be accessible from.
Reported EPS vs. consensus estimate
| Report date | EPS est. | EPS actual | Surprise | Revenue |
|---|---|---|---|---|
| Aug 6, 2026 | -0.09 | -0.09 | Miss -2.9% | — |
| May 7, 2026 | -0.13 | -0.06 | Beat 53.8% | — |
| Feb 27, 2026 | -0.14 | -0.11 | Beat 21.4% | — |
| Nov 5, 2025 | -0.17 | -0.13 | Beat 23.5% | — |
| Aug 7, 2025 | -0.21 | -0.16 | Beat 23.8% | — |
| May 14, 2025 | -0.25 | -0.17 | Beat 32.0% | — |
| SC 13G/A | Jul 27, 2026 | 2026-07-27 16:25:23 | View |
| 8-K | Jul 15, 2026 | 2026-07-15 16:46:28 | View |
| 4 | Jun 11, 2026 | 2026-06-11 16:27:20 | View |
| 4 | Jun 11, 2026 | 2026-06-11 16:26:17 | View |
| 4 | Jun 11, 2026 | 2026-06-11 16:25:40 | View |
| 4 | Jun 11, 2026 | 2026-06-11 16:23:47 | View |
Proxy statement (DEF 14A) disclosures
TTM vs. 5-year historical average (annual ratios)
| Metric | ALDX | Historical (5Y) / ref | Status |
|---|---|---|---|
| P/E ratio (TTM) | -1.7x | -6.1x · sector 20.7x | Discount |
| Forward P/E (FY26E) | -1.9x | EPS est. -0.34 | In line |
| Price / Book | 1.0x | 3.3x | Discount |
| Price / Sales | — | — | n/a |
| EV / EBITDA | 0.3x | -4.0x | Discount |
| Return on equity | -53.1% | — | Weak |
| Gross margin | 0.0% | 0.0% | n/a |
| Debt / Equity | 0.00 | 0.18 | Conservative |
| Piotroski / Altman Z | 2/9 | Z -12.63 | Distress |
Discounted cash flow model
Free float vs. closely held shares
13F institutional holdings are not available in the current data plan.
SEC Form 4 filings
| Date | Insider | Role | Type | Shares @ price | Value |
|---|---|---|---|---|---|
| Jun 9, 26 | Miller-Rich Nancy | director | A-Award | 70,000 @ $1.72 | $120.4K |
| Jun 9, 26 | Miller-Rich Nancy | director | A-Award | 3,318 @ $1.72 | $5.71K |
| Jun 9, 26 | Douglas Richard | director | A-Award | 70,000 @ $1.72 | $120.4K |
| Jun 9, 26 | Douglas Richard | director | A-Award | 19,909 @ $1.72 | $34.24K |
| Jun 9, 26 | Douglas Richard | director | A-Award | 2,323 @ $1.72 | $4.00K |
| Jun 9, 26 | Phillips Gary M. | director | A-Award | 70,000 @ $1.72 | $120.4K |
| Jun 9, 26 | Phillips Gary M. | director | A-Award | 6,636 @ $1.72 | $11.41K |
| Jun 9, 26 | Phillips Gary M. | director | A-Award | 4,977 @ $1.72 | $8.56K |